Hormone Replacement Therapy Regimens

Optimal Regimen Based on Clinical Needs

The American College of Obstetricians and Gynecologists recommends transdermal 17β-estradiol patches releasing 50-100 μg daily administered continuously, with oral medroxyprogesterone acetate (MPA) 10 mg daily added for 12-14 days every 28 days for hormone replacement therapy in women with premature ovarian insufficiency 1, 2
The Endocrine Society suggests that transdermal 17βE is preferred over oral formulations due to avoidance of first-pass hepatic metabolism, better cardiovascular risk profile, improved bone mass accrual, and lower risk of venous thromboembolism 1, 2, 7, 8
MPA is an effective progestin option because it provides complete endometrial protection when used at appropriate doses, and 10 mg daily for 12-14 days per month is sufficient for sequential regimens 2, 4, 6

The North American Menopause Society recommends adjusting estrogen dose based on symptom control and patient tolerance, and monitoring for side effects, particularly in long-term use 6, 8

The American College of Obstetricians and Gynecologists suggests that if MPA is not tolerated, micronized progesterone (MP) is the preferred alternative, with a dose of 200 mg daily for 12-14 days per month in sequential regimens 2, 4
The Endocrine Society notes that MP has a more favorable cardiovascular and thrombotic risk profile compared to synthetic progestogens 7

The American Heart Association recommends considering using micronized progesterone instead of MPA for women with cardiovascular risk factors 7, 4
The American College of Obstetricians and Gynecologists suggests that HRT should be continued until the average age of natural menopause (45-55 years) in women with premature ovarian insufficiency 6, 8